Abstract
A CZE method was developed and validated for the analysis of Olmesartan medoxomil (OLMD) in tablets. The influences of pH, buffer concentration, applied voltage and capillary temperature on the migration time of OLMD were investigated. About 50 mM pH 6.5 phosphate buffer were used as background electrolyte. The optimum instrument parameters were found to be 30 °C temperature with 30 kV applied voltage and diode array detection was carried out at 210 nm. OLMD was hydrodynamically injected (P inj = 50 mbar, t inj = 3 s) and an internal standard, diflunisal (IS), was used to improve the precision and repeatability. Under these conditions, the migration time of OLMD was 2.32 min and the total analysis time was shorter than 5 min. Linearity range for the developed method was found to be 2.0–50.0 μg mL−1 and the limit of detection was 0.5 μg mL−1. The developed method was applied for the analysis of OLMD in pharmaceutical tablet formulations.
This is a preview of subscription content, access via your institution.


References
Koike H, Konse T, Sada T, Ikeda T, Hyogo S, Hinman D, Saito H, Yanagisawa H (2003) Ann Rep Sankyo Res Lab 55:1–91
Mire DE, Silfani TN, Pugsley MK (2005) J Cardiovasc Pharm 46:585–593
Kobayashi N, Fujimori I, Watanabe M, Ikeda T (2000) Anal Biochem 287:272–278
Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y, Koike H (1996) J Med Chem 39:323–338
Web page about the chemical and physical properties of Olmesartan Medoxomil: http://www.rxlist.com/cgi/generic/benicar.htm
Unger T, McInnes GT, Neutel JM, Böhm M (2004) Drugs 64:2731–2739
Altria KD, Chen AB, Clohs L (2001) LCGC North America 19:972, 974, 976, 978, 980, 982, 984–985
Morzunova TG (2006) Pharm Chem J 40:158–170
Holzgrabe U (2005) Pharm Ind 67:1209–1213
Holzgrabe U, Brinz D, Kopec S, Weber C, Bitar Y (2006) Electrophoresis 27:2283–2292
Bardelmeijer HA, Lingeman H, De Ruiter C, Underberg WJ (1998) J Chromatogr A 807:3–26
Gonzalez L, Akesolo U, Jimenez RM, Alonso RM (2002) Electrophoresis 23:223–229
Hillaert S, Van den Bossche W (2002) J Chromatogr A 979:323–333
Celebier M, Altinoz S (2007) Die Pharm 62:419–422
ICH (2005) Steering Committee. Validation of analytical procedures: Text and Methodology Q2(R1). Harmonized Tripartite Guideline
Fabre H, Altria K (2001) LC–GC 302–310
Taverniers I, Loose MD, Bockstaele EV (2004) Trends Anal Chem 23:480–490
Taverniers I, Loose MD, Bockstaele EV (2004) Trends Anal Chem 23:535–552
Mayer BX (2001) J Chromatogr A 907:21–37
Hansen HK, Hansen SH, Kraunsoe M, Petersen GM (1999) Eur J Pharm Sci 9:41–46
Acknowledgments
The authors thank Daiichi Sankyo for their kind supply of pure Olmesartan Medoxomil and Pfizer to supply Olmetec® (10, 20, 40 mg) tablets.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Çelebier, M., Altinöz, S. Development of a CZE Method for the Determination of Olmesartan Medoxomil in Tablets. Chroma 66, 929–933 (2007). https://doi.org/10.1365/s10337-007-0424-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-007-0424-2